CASALI, PAOLO GIOVANNI
CASALI, PAOLO GIOVANNI
Dipartimento di Oncologia ed Emato-Oncologia
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry
2022 B. Vincenzi, A. Napolitano, A. Comandone, R. Sanfilippo, S. Celant, P.P. Olimpieri, S. Di Segni, P. Russo, P.G. Casali
Rare cancers : not all together in clinical studies!
2022 P.G. Casali, L. Licitra, A.M. Frezza, A. Trama
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
2022 A.M. Frezza, S. Stacchiotti, F. Chibon, J. Coindre, A. Italiano, C. Romagnosa, S. Bagué, A.P. Dei Tos, L. Braglia, E. Palmerini, V. Quagliuolo, J.M. Broto, A. Lopez Pousa, G. Grignani, A. Brunello, J. Blay, R.D. Beveridge, I. Lugowska, T. Lesluyes, R. Maestro, F.D. Merlo, P.G. Casali, A. Gronchi
Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature
2022 V. Nasca, A.M. Frezza, C. Morosi, C. Buonomenna, A. Parafioriti, G. Zappalà, F. Bini, P.G. Casali, M. Loppini, S. Stacchiotti
Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2)
2022 E. Palmerini, C. Meazza, A. Tamburini, G. Bisogno, V. Ferraresi, S.D. Asaftei, G.M. Milano, L. Coccoli, C. Manzitti, R. Luksch, M. Serra, M. Gambarotti, D.M. Donati, K. Scotlandi, R. Bertulli, C. Favre, A. Longhi, M.E. Abate, S. Perrotta, M. Mascarin, P. D'Angelo, M. Cesari, E.L. Staals, E. Marchesi, E. Carretta, T. Ibrahim, P.G. Casali, P. Picci, F. Fagioli, S. Ferrari
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial
2022 S. Pasquali, E. Palmerini, V. Quagliuolo, J. Martin-Broto, A. Lopez-Pousa, G. Grignani, A. Brunello, J.-. Blay, O. Tendero, R. Diaz-Beveridge, V. Ferraresi, I. Lugowska, G. Infante, L. Braglia, D.F. Merlo, V. Fontana, E. Marchesi, D.M. Donati, E. Palassini, G. Bianchi, A. Marrari, C. Morosi, S. Stacchiotti, S. Bague, J.M. Coindre, A.P. Dei Tos, P. Picci, P. Bruzzi, R. Miceli, P.G. Casali, A. Gronchi, C. Dani, C. Villa, A. Messina, L. Rusi, A.M. Nuzzo, C. Nuzzo, A. De Paoli, A. Buonadonna, A. Comandone, A. Boglione, L. Livi, D. Greto, N. Riva, M. Monti, E. Pennacchioli, T. De Pas, V. Ippolito, P. Ledesma, A. Redondo, C. Valverde, R. Bratos, J. Cruz, J. Martinez Trufero, R. Cubedo, I. Sevilla, P. Luna, R. Lopez, P. Sancho, O. Bally, M. Brahmi, I. Ray-Coquard, P. Cassier, N. Marques, L. Tassy, P. Boudou-Rouquette, C. Tlemsani, J. Alexandre, F. Goldwasser, E. Bompas, F. Rolland, C. Perrin, M. Talarmin, A. Italiano, M. Toulmonde, M. Laramas, J.-. Bay, P. Dubray-Longeras, P. Rutkowski
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
2022 S. Hidalgo-Ríos, J. Carrillo-García, D.S. Moura, S. Stacchiotti, A. López-Pousa, A. Redondo, A. Italiano, A. Gutiérrez, G. Grignani, N. Hindi, J. López-Guerrero, X.G.D. Muro, J.M. Trufero, E. Palmerini, A.S. García, D. Bernabeu, A. Le Cesne, P.G. Casali, J. Blay, J. Cruz Jurado, J. Martin-Broto
Systemic treatment in advanced phyllodes tumor of the breast : a multi-institutional European retrospective case-series analyses
2022 E. Palassini, O. Mir, G. Grignani, B. Vincenzi, H. Gelderblom, A. Sebio, C. Valverde, G.G. Baldi, A. Brunello, G.G. Cardellino, A. Marrari, G. Badalamenti, J. Martin-Broto, V. Ferraresi, M. Libertini, S. Turano, I. Gataa, P. Collini, A.P.D. Tos, M. Gennaro, F. Bini, S. Provenzano, S.L. Vullo, L. Mariani, A. Le Cesne, P.G. Casali
Is rare cancer care organized at national health system level? Multiple case study in six EU countries
2022 J. Prades, A. Trama, P.G. Casali, J. Emile, N. Gaspar, R. Janavicius, R. Jančiauskienė, S. Karjalainen, K. Kopeckova, L. Pylkkänen, M. Svoboda, J.M. Borras
Gastrointestinal stromal tumours : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
2022 P.G. Casali, J.Y. Blay, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J.V.M.G. Bovee, K. Boye, T. Brodowicz, A. Buonadonna, E. De Alava, A.P. Dei Tos, X.G. Del Muro, A. Dufresne, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, R. Haas, A.B. Hassan, N. Hindi, P. Hohenberger, H. Joensuu, R.L. Jones, C. Jungels, P. Jutte, B. Kasper, A. Kawai, K. Kopeckova, D.A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez-Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A.B. Miah, O. Mir, M. Montemurro, C. Morosi, E. Palmerini, M.A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A.A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, S.J. Strauss, K.S. Hall, A. Trama, M. Unk, M.A.J. van de Sande, W.T.A. van der Graaf, W.J. van Houdt, T. Frebourg, A. Gronchi, S. Stacchiotti
Ethical issues in oncology practice: a qualitative study of stakeholders' experiences and expectations
2022 C. Crico, V. Sanchini, P.G. Casali, G. Pravettoni
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
2022 B. Vincenzi, A. Napolitano, M. Fiocco, O. Mir, P. Rutkowski, J. Blay, P. Reichardt, H. Joensuu, E. Fumagalli, S. Gennatas, N. Hindi, M. Nannini, M. Spalato Ceruso, A. Italiano, G. Grignani, A. Brunello, S. Gasperoni, T. De Pas, G. Badalamenti, M.A. Pantaleo, W.J. van Houdt, N.S. Ijzerman, N. Steeghs, H. Gelderblom, I.M.E. Desar, J. Falkenhorst, M. Silletta, M. Sbaraglia, G. Tonini, J. Martin-Broto, P. Hohenberger, A. Le Cesne, R.L. Jones, A.P. Dei Tos, A. Gronchi, S. Bauer, P.G. Casali
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation
2021 V. Zuco, S. Pasquali, M. Tortoreto, S. Brich, S. Percio, G.P. Dagrada, C. Colombo, R. Sanfilippo, C. Lauricella, M. Gounder, R. El Bezawy, M. Barisella, A.P. Dei Tos, P.G. Casali, A. Gronchi, S. Stacchiotti, N. Zaffaroni
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
2021 S. Stacchiotti, A.B. Miah, A.M. Frezza, C. Messiou, C. Morosi, A. Caraceni, C.R. Antonescu, J. Bajpai, E. Baldini, S. Bauer, R. Biagini, S. Bielack, J.Y. Blay, S. Bonvalot, I. Boukovinas, J.V.M.G. Bovee, K. Boye, T. Brodowicz, D. Callegaro, E. De Alava, M. Deoras-Sutliff, A. Dufresne, M. Eriksson, C. Errani, A. Fedenko, V. Ferraresi, A. Ferrari, C.D.M. Fletcher, X. Garcia del Muro, H. Gelderblom, R.A. Gladdy, F. Gouin, G. Grignani, J. Gutkovich, R. Haas, N. Hindi, P. Hohenberger, P. Huang, H. Joensuu, R.L. Jones, C. Jungels, B. Kasper, A. Kawai, A. Le Cesne, F. Le Grange, A. Leithner, H. Leonard, A. Lopez Pousa, J. Martin Broto, O. Merimsky, P. Merriam, R. Miceli, O. Mir, M. Molinari, M. Montemurro, G. Oldani, E. Palmerini, M.A. Pantaleo, S. Patel, S. Piperno-Neumann, C.P. Raut, V. Ravi, A.R.A. Razak, P. Reichardt, B.P. Rubin, P. Rutkowski, A.A. Safwat, C. Sangalli, G. Sapisochin, M. Sbaraglia, S. Scheipl, P. Schoffski, D. Strauss, S.J. Strauss, K. Sundby Hall, W.D. Tap, A. Trama, A. Tweddle, W.T.A. van der Graaf, M.A.J. Van De Sande, W. Van Houdt, G. van Oortmerssen, A.J. Wagner, M. Wartenberg, J. Wood, N. Zaffaroni, C. Zimmermann, P.G. Casali, A.P. Dei Tos, A. Gronchi
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma
2021 L. Mannarino, I. Craparotta, S. Ballabio, R. Frapolli, M. Meroni, E. Bello, N. Panini, M. Callari, R. Sanfilippo, P.G. Casali, M. Barisella, C. Fabbroni, S. Marchini, M. D'Incalci
Evaluating the effectiveness of clinical ethics committees : a systematic review
2021 C. Crico, V. Sanchini, P.G. Casali, G. Pravettoni
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
2021 A.M. Frezza, V. Ravi, S. Lo Vullo, B. Vincenzi, F. Tolomeo, T.W.-. Chen, P. Teterycz, G.G. Baldi, A. Italiano, N. Penel, A. Brunello, F. Duffaud, N. Hindi, S. Iwata, A. Smrke, A. Fedenko, H. Gelderblom, W. Van Der Graaf, A. Vozy, E. Connolly, M. Grassi, R.S. Benjamin, J.-. Broto, G. Grignani, R.L. Jones, A. Kawai, A. Tysarowski, L. Mariani, P.G. Casali, S. Stacchiotti
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
2021 P.G. Casali, A. Le Cesne, A.P. Velasco, D. Kotasek, P. Rutkowski, P. Hohenberger, E. Fumagalli, I.R. Judson, A. Italiano, H. Gelderblom, N. Penel, J.T. Hartmann, F. Duffaud, D. Goldstein, J. Martin-Broto, A. Gronchi, E. Wardelmann, S. Marreaud, J.R. Zalcberg, S. Litiere, J.-. Blay
Predictive value of MRP-1 in localized high-risk soft tissue sarcomas: A translational research associated to ISG-STS 1001 randomized phase III trial
2021 J. Martin-Broto, M. Lopez-Alvarez, D.S. Moura, R. Ramos, P. Collini, C. Romagosa, S. Bague, S.L. Renne, M. Barisella, V. Velasco, J.-. Coindre, D. Lopez-Lopez, J. Dopazo, M. Gambarotti, L. Braglia, D.F. Merlo, E. Palmerini, S. Stacchiotti, V.L. Quagliuolo, A. Lopez-Pousa, G. Grignani, J.-. Blay, A. Brunello, A. Gutierrez, C. Valverde, N. Hindi, A.P. Dei Tos, P. Picci, P.G. Casali, A. Gronchi
Data protection and research in the European Union: a major step forward, with a step back
2021 P.G. Casali, M. Vyas